TCRX FY 2020 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$65M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$19M-1796.5% margin

Operating Income

-$26M-2417.8% margin

Net Income

-$26M-2408.0% margin

EPS (Diluted)

$-1.04

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$7M

Stock-Based Comp.

$515,000

Balance Sheet

Total Assets

$50M

Total Liabilities

$92M

Stockholders' Equity

-$42M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$19M	-$9M	-106.4%
Operating Income	-$26M	-$14M	-84.6%
Net Income	-$26M	-$14M	-91.3%